Log in or register to see all Alerts
New HTA Decisions in England
July 2019
Drug name
ADCETRIS® (Brentuximab vedotin)
Seattle Genetics
Decision date
Therapeutic area
Blood and immune system conditions
Therapeutic sub area
Blood and bone marrow cancers
Recommended with restrictions
Brentuximab vedotin is recommended as an option for treating CD30‑positive cutaneous T‑cell lymphoma (CTCL) after at least one systemic therapy in adults.
Decision Detail
It is recommended only if - (1) the patient has mycosis fungoides at stage IIB or over OR primary cutaneous anaplastic large cell lymphoma OR Sézary syndrome and (2) the company provides brentuximab vedotin according to the commercial arrangement.
The evidence for the clinical effectiveness of brentuximab vedotin comes from ALCANZA, an international, multi-centre, open-label randomised controlled trial comparing brentuximab vedotin with physician's choice of treatment (either methotrexate or bexarotene). Brentuximab vedotin was found to improve progression-free survival and had longer responses compared with current treatment options, it may also be used as a bridge treatment in CTCL patients prior to stem cell transplants. Cost-effectiveness estimates for brentuximab vedotin compared with current treatments were less than £30,000 per quality-adjusted life year gained, therefore considered a cost-effective use of NHS resources.